Headache Treatments
Michael A. Rogawski, M.D., Ph.D.
  • Home
  • Search
  • Testing Routine Blood Migraine
  • Acute Migraine Treatments
  • Behavioral Therapy
  • Botox
  • Breastfeeding
  • Butterbur
  • Cannabinoids
  • Cerebral Vascular Anatomy
  • CGRP Antibodies and Gepants
  • Children and Adolescents
  • Chronic Pain / Back Pain
  • Cluster Headache Treatment
  • Contraception - Birth Control
  • Depression Screening PHQ-2 and PHQ-9
  • Deprescribing/ Withdrawing Medications
  • Devices
  • Emergency Department Treatment / Steroid Taper
  • Epilepsy/Seizure Drugs in Development
  • Exercise
  • HIT-6 Headache Impact Test
  • Headache Tracking
  • Headache Types
  • Hemiplegic Migraine
  • High and Low Pressure Headache
  • Hypertension Guidlines
  • Indomethacin Responsive Headaches
  • IV Infusion Protocols
  • Magnesium, Nutritional Supplements and Alternative
  • Medication Overuse Headache
  • Menopause - Menopausal Vasomotor Symptoms
  • Menstrual Migraine
  • MIDAS (Migraine Disability Assessment) and ASC-12
  • Migraine Mimics
  • Neck Pain; Spinal Anatomy & Dermtomes
  • Nerve Blocks
  • Nonpharmacological Measures
  • NSAID
  • Occipital Epilepsy
  • Publications
  • Posttraumatic Headache
  • Pregnancy
  • Preventative Migraine Treatments
  • Prodrome and Aura
  • Red Flag Symptoms
  • Sleep - Insomnia
  • SphenoCath
  • Sphenopalatine Ganglion Block
  • Status migrainosus
  • Tension Type Headache
  • Thunderclap Headache
  • Tinnitus
  • Triggers/Caffeine
  • Vestibular Migraine
  • Lawrence Robbins: Advanced Headache Therapy

FDA Approved Cannabinoids

Marinol (dronabinol)
AbbVie Inc.
Schedule III Controlled Substance
Unimed Pharmaceuticals, a subsidiary of Solvay Pharmaceuticals, was initially granted approval in 1985 for Marinol in a fixed-dose pill form for nausea. In 1992, appetite stimulation was added to its indications. It was classified as a Schedule I drug until it was moved to Schedule III in 1999. Marinol is manufactured by Patheon Softgels, Inc., for Abbvie Inc.
Schedule III Controlled Substance
Seizure and seizure-like activity have been reported in patients receiving dronabinol.

Syndros (dronabinol solution) oral solution
Insys Therapeutics, Inc.
​Schedule II Controlled Substance
50% w/w dehydrated alcohol, propylene glycol, polyethylene glycol 400, sucralose, methyl paraben, propyl paraben, BHA, water
Seizures and seizure-like activity have been reported in patients receiving dronabinol.

Cesamet (nabilone)
Meda Pharmaceuticals, Inc. (Valiant Pharmaceuticals)
Schedule II Controlled Substance
No mention of seizures in package insert.

Epidiolex (Cannabidiol)

Abuse Liability Studies
FDA analysis of preclinical and clinical abuse liability studies are discussed in FDA slides from April 19, 2018 advisory meeting, available here.